🇺🇸 FDA
Patent

US 10226487

Derivation and self-renewal of lsl1+ cells and uses thereof

granted A61KA61K35/34

Quick answer

US patent 10226487 (Derivation and self-renewal of lsl1+ cells and uses thereof) held by IsletOne AB expires Mon Mar 07 2039 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
IsletOne AB
Grant date
Tue Mar 12 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Mar 07 2039 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
7
CPC classes
A61K, A61K35/34